ArticleDiscover oncology2025
Comprehensive analysis of the role of NEDD4 in pan-cancer and experimental verification of its role in KIRC progression.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neural precursor cell expressed developmentally down-regulated protein 4 (NEDD4) serves as the founding member of the HECT ubiquitin ligase family involved in protein degradation within the ubiquitin-proteasome system. Although numerous studies have demonstrated the involvement of NEDD4 in carcinogenesis by regulating the ubiquitylation-mediated turnover of different substrates, there is still a lack of pan-cancer studies investigating its relevance across various types of cancers. In this study, we aimed to conduct a comprehensive pan-cancer analysis of NEDD4 and elucidate its role in tumorigenesis Firstly, the results of our study unveiled that NEDD4 was dysregulated in a variety of tumors including Kidney Renal Clear Cell Carcinoma (KIRC). Survival analysis revealed that the dysregulation of NEDD4 expression was associated with the patient prognosis. Additionally, immunoassays indicated that NEDD4 might be associated with the expression of multiple tumor immune checkpoints. Finally, we further analyzed NEDD4 in KIRC and found that NEDD4 may regulate KIRC apoptosis by regulating PI3K-AKT signaling. Cell experiments confirmed that the knockdown of NEDD4 promoted the proliferation, invasion, and migration of A498 cells. Furthermore, PTEN, a negative regulator of PI3K-AKT signaling, was found to be regulated by NEDD4. In conclusion, the results of this study suggest that NEDD4 is a potential tumor prognostic biomarker and immunotherapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.